نتائج البحث - "Glucagon-Like Peptide-1 Receptor / agonists"

1

دورية أكاديمية

Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy

المؤلفون: Cesta, Carolyn E., Rotem, Ran, Bateman, Brian T., Chodick, Gabriel, Cohen, Jacqueline M., Furu, Kari, Gissler, Mika, Huybrechts, Krista F., Kjerpeseth, Lars J., Leinonen, Maarit K., Pazzagli, Laura, Zoega, Helga, Seely, Ellen W., Patorno, Elisabetta, Hernández-Díaz, Sonia

المساهمون: Faculty of Medicine

مصطلحات موضوعية: Cohort Studies, Diabetes Mellitus, Type 2/drug therapy, Dipeptidyl-Peptidase IV Inhibitors/therapeutic use, Female, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptide-1 Receptor/agonists, Humans, Hypoglycemic Agents/adverse effects, Insulin/adverse effects, Pregnancy, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Sulfonylurea Compounds/adverse effects, Internal Medicine

وصف الملف: 144-152

العلاقة: JAMA Internal Medicine; 184(2); http://www.scopus.com/inward/record.url?scp=85181034956&partnerID=8YFLogxKTest; Cesta , C E , Rotem , R , Bateman , B T , Chodick , G , Cohen , J M , Furu , K , Gissler , M , Huybrechts , K F , Kjerpeseth , L J , Leinonen , M K , Pazzagli , L , Zoega , H , Seely , E W , Patorno , E & Hernández-Díaz , S 2024 , ' Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy ' , JAMA Internal Medicine , vol. 184 , no. 2 , pp. 144-152 . https://doi.org/10.1001/jamainternmed.2023.6663Test; 215155202; 198ef4fd-ee4e-4302-b551-12e929142bad; 85181034956; https://hdl.handle.net/20.500.11815/4806Test

الإتاحة: https://doi.org/20.500.11815/4806Test
https://doi.org/10.1001/jamainternmed.2023.6663Test
https://hdl.handle.net/20.500.11815/4806Test

View record in BASE

2

دورية أكاديمية

Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia

المؤلفون: de Oliveira Costa, J, Lin, J, Milder, TY, Greenfield, JR, Day, RO, Stocker, SL, Neuen, BL, Havard, A, Pearson, SA, Falster, MO

المصدر: urn:ISSN:1462-8902 ; urn:ISSN:1463-1326 ; Diabetes, Obesity and Metabolism, 26, 7, 2787-2795

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/1959.4/102333Test; https://unsworks.unsw.edu.au/bitstreams/4eed81ac-aad7-4fff-a5db-c74f19484d11/downloadTest; https://doi.org/10.1111/dom.15597Test

الإتاحة: https://doi.org/10.1111/dom.15597Test
http://hdl.handle.net/1959.4/102333Test
https://unsworks.unsw.edu.au/bitstreams/4eed81ac-aad7-4fff-a5db-c74f19484d11/downloadTest

View record in BASE

3

دورية أكاديمية

Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.

المؤلفون: Setor K Kunutsor, Francesco Zaccardi, Victoria G Balasubramanian, Clare L Gillies, Vanita R Aroda, Samuel Seidu, Melanie J Davies, Kamlesh Khunti

مصطلحات موضوعية: Uncategorized, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, meta-analysis, meta-regression, sodium-glucose cotransporter-2 inhibitors, type 2 diabetes

العلاقة: 2381/25325488.v1; https://figshare.com/articles/journal_contribution/Glycaemic_control_and_macrovascular_and_microvascular_outcomes_in_type_2_diabetes_Systematic_review_and_meta-analysis_of_cardiovascular_outcome_trials_of_novel_glucose-lowering_agents_/25325488Test

الإتاحة: https://figshare.com/articles/journal_contribution/Glycaemic_control_and_macrovascular_and_microvascular_outcomes_in_type_2_diabetes_Systematic_review_and_meta-analysis_of_cardiovascular_outcome_trials_of_novel_glucose-lowering_agents_/25325488Test

View record in BASE

4

دورية أكاديمية

Additional file 1 of The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis

المؤلفون: Muhammad Usman Ali, G. B. John Mancini, Donna Fitzpatrick-Lewis, Kim A. Connelly, Eileen O’Meara, Shelley Zieroth, Diana Sherifali

مصطلحات موضوعية: Medicine, Sociology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Meta-analysis, Sodium-glucose co-transporter 2 inhibitors, Glucagon-like peptide-1 receptor agonists, Cardiorenal outcomes

العلاقة: https://figshare.com/articles/journal_contribution/Additional_file_1_of_The_effectiveness_of_sodium-glucose_co-transporter_2_inhibitors_on_cardiorenal_outcomes_an_updated_systematic_review_and_meta-analysis/25231240Test

الإتاحة: https://doi.org/10.6084/m9.figshare.25231240.v1Test
https://figshare.com/articles/journal_contribution/Additional_file_1_of_The_effectiveness_of_sodium-glucose_co-transporter_2_inhibitors_on_cardiorenal_outcomes_an_updated_systematic_review_and_meta-analysis/25231240Test

View record in BASE

5

دورية أكاديمية

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

المؤلفون: Neuen, BL, Heerspink, HJL, Vart, P, Claggett, BL, Fletcher, RA, Arnott, C, de Oliveira Costa, J, Falster, MO, Pearson, SA, Mahaffey, KW, Neal, B, Agarwal, R, Bakris, G, Perkovic, V, Solomon, SD, Vaduganathan, M

المصدر: urn:ISSN:0009-7322 ; urn:ISSN:1524-4539 ; Circulation, 149, 6, 450-462

مصطلحات موضوعية: Heart Disease, Cardiovascular, Diabetes, Clinical Research, Kidney Disease, 5 Development of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6 Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Metabolic and endocrine, Renal and urogenital, 3 Good Health and Well Being, Humans, Middle Aged, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Diabetic Nephropathies, Canagliflozin, Glucagon-Like Peptide-1 Receptor Agonists, Albuminuria, Cardiovascular Diseases, Kidney, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1, heart failure, mortality, treatment outcome, anzsrc-for: 1102 Cardiorespiratory Medicine and Haematology

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/1959.4/unsworks_84901Test; https://unsworks.unsw.edu.au/bitstreams/f7a94e6a-e786-4975-b116-8384bfa0e43c/downloadTest; https://doi.org/10.1161/CIRCULATIONAHA.123.067584Test

الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.123.067584Test
http://hdl.handle.net/1959.4/unsworks_84901Test
https://unsworks.unsw.edu.au/bitstreams/f7a94e6a-e786-4975-b116-8384bfa0e43c/downloadTest

View record in BASE

6

دورية أكاديمية

Additional file 1 of The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis

المؤلفون: Muhammad Usman Ali, G. B. John Mancini, Donna Fitzpatrick-Lewis, Kim A. Connelly, Eileen O’Meara, Shelley Zieroth, Diana Sherifali

مصطلحات موضوعية: Medicine, Sociology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Meta-analysis, Sodium-glucose co-transporter 2 inhibitors, Glucagon-like peptide-1 receptor agonists, Cardiorenal outcomes

العلاقة: https://figshare.com/articles/journal_contribution/Additional_file_1_of_The_effectiveness_of_sodium-glucose_co-transporter_2_inhibitors_on_cardiorenal_outcomes_an_updated_systematic_review_and_meta-analysis/25231240Test

الإتاحة: https://doi.org/10.6084/m9.figshare.25231240.v1Test

View record in BASE

7

دورية أكاديمية

Glucagon-like peptide 1 receptor agonists in the treatment of patients with type 2 diabetes and metabolically-associated steatosic liver disease. Review ; Агоністи рецепторів глюкагоноподібного пептиду-1 у лікуванні пацієнтів із цукровим діабетом 2 типу та метаболічно-асоційованою стеатозною хворобою печінки. Огляд

المؤلفون: Ткач, С. М.

المصدر: Clinical Endocrinology and Endocrine Surgery; No. 1 (2024); 44-50 ; Clinical Endocrinology and Endocrine Surgery; № 1 (2024); 44-50 ; 2519-2582 ; 1818-1384 ; 10.30978/10.30978/CEES-2024-1

مصطلحات موضوعية: цукровий діабет 2 типу, метаболічно‑асоційована стеатозна хвороба печінки, агоністи рецепторів глюкагоноподібного пептиду‑1, type 2 diabetes, metabolic‑associated steatotic liver disease, glucagon‑like peptide‑1 receptor agonists